Study summary · research use only
[Recent progress and novel perspectives on obesity pharmacotherapy]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses recent data on clinical trials of novel weight-loss drugs nearing potential market entry, in the context of rising obesity prevalence and its metabolic and cardiovascular risks. It notes that lifestyle modification alone has shown modest long-term results and that the authors characterized bariatric surgery as the leading treatment option to date, though associated with nutritional and metabolic complications, and states there are currently few marketed antiobesity agents due partly to prior medication withdrawals over safety concerns. The review discusses lorcaserin (a selective serotonin 5-HT2c agonist), tesofensine (a triple monoamine reuptake inhibitor), liraglutide (a GLP-1 analogue), cetilistat (a gastrointestinal lipase inhibitor), and combination therapies including bupropion/naltrexone, bupropion/zonisamide, phentermine/topiramate, and pramlintide/metreleptin.
Abstract
Obesity prevalence has risen dramatically over the past decades, which poses a great number of patients at risk of metabolic and cardiovascular complications. Long-term efficacy of lifestyle modification isolated has shown to be modest which, therefore, urges the need of more aggressive interventions such as adjuvant pharmacotherapy or the more radical surgical approach. Bariatric surgery has proven to date to be the most effective treatment, although it may be associated with nutritional and metabolic complications not yet completely recognized. By contrast, there is limited availability of antiobesity agents currently in the market, as well as historical facts involving the suspension of previously existing medications due to safety concerns. This article aims to present recent data on clinical trials of novel weight-loss drugs with short perspective to enter the market, if approved by the regulatory agencies. This review will discuss the efficacy and safety of these compounds, which include lorcaserin (selective serotonin 5-HT2c agonist), tesofensine (triple monoamine reuptake inhibitor), liraglutide (GLP-1 analogue) and cetilistat (gastrointestinal lipase inhibitor), as well as the combination therapies of bupropion/naltrexone, bupropion/zonisamide, phentermine/topiramate and pramlintide/metreleptin.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.